Minnelideâ„¢ Capsules Alone and in Combination With Paclitaxel in Advanced Gastric Cancer
- First Posted Date
- 2022-10-04
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Minneamrita Therapeutics LLC
- Target Recruit Count
- 36
- Registration Number
- NCT05566834
- Locations
- 🇰🇷
Samsung Medical Center, Soeul, Korea, Republic of
Minnelide Along With Abraxane Plus Gemcitabine in Patients With Metastatic Adenocarcinoma of the Pancreas
Phase 1
Recruiting
- Conditions
- Metastatic Adenocarcinoma of the Pancreas
- Interventions
- Combination Product: Minnelide
- First Posted Date
- 2022-09-28
- Last Posted Date
- 2022-12-09
- Lead Sponsor
- Minneamrita Therapeutics LLC
- Target Recruit Count
- 36
- Registration Number
- NCT05557851
- Locations
- 🇰🇷
Samsung Medical Center, Soeul, Korea, Republic of
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelideâ„¢ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced CancerBreast CancerPancreatic CancerProstate Cancer MetastaticSolid Carcinoma of StomachCancer of StomachColo-rectal CancerSolid TumorGastric CancerSolid Carcinoma
- Interventions
- Drug: Minnelideâ„¢Capsules
- First Posted Date
- 2017-04-26
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Minneamrita Therapeutics LLC
- Target Recruit Count
- 66
- Registration Number
- NCT03129139
- Locations
- 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
A Phase II, International Open Label Trial of Minnelideâ„¢ in Patients With Refractory Pancreatic Cancer
- First Posted Date
- 2017-04-18
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Minneamrita Therapeutics LLC
- Target Recruit Count
- 19
- Registration Number
- NCT03117920
- Locations
- 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸Moores UC San Diego Cancer Center, La Jolla, California, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
Study of Minnelideâ„¢ in Patients With Advanced GI Tumors
Phase 1
Completed
- Conditions
- Advanced Gastrointestinal Tumors
- Interventions
- Drug: Minnelideâ„¢ 001
- First Posted Date
- 2013-08-23
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- Minneamrita Therapeutics LLC
- Target Recruit Count
- 45
- Registration Number
- NCT01927965
- Locations
- 🇺🇸
Virginia G. Piper Cancer Center at Scottsdale Healthcare, Scottsdale, Arizona, United States
🇺🇸University of Minnesota Masonic Cancer Clinic, Minneapolis, Minnesota, United States
© Copyright 2025. All Rights Reserved by MedPath